4 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Complete resection without lymphadenectomy; adjuvant imatinib 3 years for high-risk (SSGXVIII); neoadjuvant imatinib to downsize when organ-sparing matters.
The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Imatinib 400 mg (800 mg for KIT exon 9); avapritinib for PDGFRA D842V; continue until progression.
The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy.
Avapritinib is the first drug for GIST driven by the PDGFRA D842V mutation, which resists every other kinase inhibitor; it is also approved for systemic mastocytosis.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Cognitive effects · NAVIGATOR, 300 or 400 mg daily, N=204 | 48% | 4.9% |
| Oedema, including periorbital and facial · NAVIGATOR, 300 or 400 mg daily, N=204 | 72% | 2% |
| Intracranial haemorrhage · Patients with GIST in the label, 3 of 267 | 1.1% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Sunitinib. Ripretinib for KIT exon 11 + 17/18 secondary mutations found on ctDNA is being tested against sunitinib in the ongoing phase 3 INSIGHT trial; its US label covers only patients who have had three or more kinase inhibitors.
Sunitinib is an anti-angiogenic pill approved for pancreatic neuroendocrine tumours, kidney cancer and GIST.
A fourth-line GIST drug that locks KIT in an off state regardless of which resistance mutation the tumour has acquired.
A blood test that reads fragments of DNA shed by the tumour, so you can genotype or monitor cancer without a needle in the tumour.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypertension · Pancreatic NET phase 3 (n=83), US label | 27% | 10% |
| Hand-foot syndrome · Pancreatic NET phase 3 (n=83), US label | 23% | 6% |
| Diarrhoea · Pancreatic NET phase 3 (Study 6, n=83), US label | 59% | 5% |
| Nausea · Pancreatic NET phase 3 (n=83), US label | 45% | 1% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypertension · INVICTUS ripretinib arm, N=85 | 14% | 7% |
| Alopecia · INVICTUS ripretinib arm, N=85 | 52% | - |
| Palmar-plantar erythrodysaesthesia · INVICTUS ripretinib arm, N=85 | 21% | - |
| Cutaneous squamous cell carcinoma · INVICTUS ripretinib arm, N=85 | 4.7% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Regorafenib, then ripretinib (INVICTUS); rechallenge or continue TKI beyond progression; clinical trials (bezuclastinib-sunitinib).
A sorafenib successor that became the first second-line drug proven to prolong life in liver cancer (2017).
A fourth-line GIST drug that locks KIT in an off state regardless of which resistance mutation the tumour has acquired.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypertension · RESORCE (n=374), US label | 31% | 15% |
| Hand-foot skin reaction · RESORCE, regorafenib after sorafenib in HCC (n=374), US label | 51% | 12% |
| Asthenia/fatigue · RESORCE (n=374), US label | 42% | 10% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypertension · INVICTUS ripretinib arm, N=85 | 14% | 7% |
| Alopecia · INVICTUS ripretinib arm, N=85 | 52% | - |
| Palmar-plantar erythrodysaesthesia · INVICTUS ripretinib arm, N=85 | 21% | - |
| Cutaneous squamous cell carcinoma · INVICTUS ripretinib arm, N=85 | 4.7% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.